- CA$1.15bn
- CA$1.06bn
- CA$450.09m
Brief: Knight Therapeutics Reports First Quarter 2023 Results
Brief: Knight Therapeutics Reports Q1 Results
Brief: Knight Therapeutics Reports Fourth Quarter And Year-End 2022 Results
Brief: Knight Announces Relaunch Of Akynzeo® In Canada
Brief: Knight Therapeutics Announces Regulatory Submission For Tafasitamab In Brazil
Brief: Knight Therapeutics assumes commercial activities and re-launches Exelon in Brazil
Brief: Knight Announces Normal Course Issuer Bid
Brief: G2s2 Capital Says Co's Unit Has Increased Its Ownership Of Knight Therapeutics
Brief: Knight Therapeutics Assumes Commercial Activities For Exelon In Colombia
Brief: Knight Therapeutics And Rigel Pharmaceuticals To Commercialize Fostamatinib In Latin America
Brief: Knight Therapeutics Reports First Quarter Results
Brief: Knight Therapeutics And Helsinn Healthcare SA Enter Into Exclusive License, Distribution, And Supply Agreement For Akynzeo And Aloxi
Canada Research Roundup: Boyd Group Services, Centerra Gold, Savaria
Brief: Knight Therapeutics Reports Fourth Quarter And Year-End 2021 Results
Brief: Knight Therapeutics Announces Approval Of Halaven In Colombia
Brief: Knight Therapeutics Inc. Announces Approval Of Lenvima® In Colombia
Canada Research Roundup: AG Growth International, Canadian Tire Corporation, Power Corporation of Canada
Brief: Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With Incyte
Brief: Knight Therapeutics Announces Health Canada Approval For Nerlynx® (Neratinib) To Treat Her2-Positive Metastatic Breast Cancer